In April 2020, right at the peak of the pandemic, Nanolek LLC and Efferon JSC teamed up to launch two innovative devices for extracorporeal blood purification on the market: Efferon LPS and Efferon CT.

Vast experience has been acquired in less than a year of collaboration on the use of hemosorption columns in patients with coronavirus infection, sepsis and septic shock.

The physicians using Efferon LPS and Efferon CT columns in their clinical practice have shared feedback on their application and noted a positive dynamics of patients’ condition and safety of used treatment in severe patients.

These findings have led to two publications in the “General Reanimatology” journal both focusing on the clinical use of the columns. The most recent one is dated December (https://www.reanimatology.com/rmt/article/view/1985) and reports on the experience of using an Efferon LPS hemosorption column in 9 patients with septic shock which has proven the efficacy and safety of the technique. A 28-day survival rate was achieved in 7 of 9 patients, a figure that markedly improves the survivability rate in severe patients suffering from sepsis and septic shock.

The multicentre randomised LASSO (Lipopolysaccharide Adsorption at Septic Shock) study organized by Efferon JSC on the premises of leading Russian medical centres will be launched in Q1 2021. The study is carried out according to GLP international standards and involves an independent contract research provider and a third-party laboratory facility.

This year, in 2021, the NANOLEK team expects to roll out a mobile application to help medical practitioners use videos showing different modes of connection of devices to perfusion pumps. These videos enable to use the new device in daily practice of resuscitators and share personal experience of using extracorporeal techniques.

Artem Vetrov, Line Manager: “The NANOLEK team is not just seeking to promote the sales of Efferon absorption columns, but is rather aiming to put these techniques into service in healthcare institutions in Russia. The point is to show the medical community the applicability of Efferon devices in patients with sepsis and cytokine storm. Our first findings in the marketplace give us a positive outlook for the future, and we have absolutely no doubts that Efferon will be used in clinical practice as before.”

Ivan Bessonov, Co-founder and Technical Director of Efferon JSC: “The results of the first year of our cooperation with NANOLEK are very satisfying for us. Their highly professional approach to promotion of our solutions on the market is what drives us to focus on research and development of new products which will be brought to the attention of the international medical community in the nearest future.”

Please keep in mind that in 2020 Efferon and NANOLEK gratuitously delivered absorption columns to the state budget healthcare institution of Moscow “City Clinical Hospital No 40” in Kommunarka, a place treating patients with new coronavirus infection, the University Hospital - Medical Research and Education Center of Moscow State University on Lomonosovsky Prospect, and several other health care institutions.